Role of CD4 cytotoxic T lymphocytes in the control of viral diseases and cancer

International Reviews of Immunology

Volumn 29, Issue 4, 2010, Pages 371-402

  Martorelli, Debora ^a   Muraro, Elena ^a   Merlo, Anna ^b   Turrini, Riccardo ^b   Rosato, Antonio ^b,c   Dolcetti, Riccardo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Cancer; CD4 T cells; Cytotoxicity; Epstein Barr virus

Indexed keywords

CD4+ T LYMPHOCYTE; CYTOTOXICITY; EPSTEIN BARR VIRUS; EXPERIENCE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOLOGY; NEOPLASM; VIRUS INFECTION;

CD4-POSITIVE T-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; VIRUS DISEASES;

EID: 77954789175     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2010.489658     Document Type: Review

References (169)

1. Mitchison NA. The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur J Immunol 1971;1:18-27.
2. Keene JA and J Forman. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982;155:768-782.
3. Krensky AM, CS Reiss, JW Mier, et al. Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc Natl Acad Sci U S A 1982;79:2365-2369.
4. Fleischer B. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature 1984;308:365-367.
5. Kennedy R and E Celis. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008;222:129-144.
6. Glimcher LH and KM Murphy. Lineage commitment in the immune system: The T helper lymphocyte grows up. Genes Dev 2000;14:1693-1711.
7. Veldhoen M, C Uyttenhove, J van Snick, et al. Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008;9:1341-1346.
8. Dardalhon V, A Awasthi, H Kwon, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008;9:1347-1355.
9. Chen Z and JJ O'Shea. Th17 cells: A new fate for differentiating helper T cells. Immunol Res 2008;41:87-102.
10. Annunziato F, L Cosmi, V Santarlasci, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849-1861.
11. Duhen T, R Geiger, D Jarrossay, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10:857-863.
12. Trifari S, CD Kaplan, EH Tran, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10:864-871.
13. Fujita H, KE Nograles, T Kikuchi, et al. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A 2009;106:21795-21800.
14. Eyerich S, K Eyerich, D Pennino, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009;119:3573-3585.
15. Reinhardt RL, SJ Kang, HE Liang, and RM Locksley. T helper cell effector fates- Who, how and where? Curr Opin Immunol 2006;18:271-277.
16. King C. New insights into the differentiation and function of T follicular helper cells. Nat Rev Immunol 2009;9:757-766.
17. Grossman WJ, JW Verbsky, W Barchet, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004;21:589-601.
18. Miyara M and S Sakaguchi. Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med 2007;13:108-116.
19. Grossman WJ, JW Verbsky, BL Tollefsen, et al. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004;104:2840-2848.
20. Chen Y, VK Kuchroo, J Inobe, et al. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994;265: 1237-1240.
21. Godfrey DI, HR MacDonald, M Kronenberg, et al. NKT cells: What's in a name? Nat Rev Immunol 2004;4:231-237.
22. Vincent MS, JE Gumperz, and MB Brenner. Understanding the function of CD1- restricted T cells. Nat Immunol 2003;4:517-523.
23. Kronenberg M and L Gapin. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002;2:557-568.
24. Suni MA, SA Ghanekar, DW Houck, et al. CD4(+)CD8(dim) T lymphocytes exhibit enhanced cytokine expression, proliferation and cytotoxic activity in response to HCMV and HIV-1 antigens. Eur J Immunol 2001;31:2512-2520.
25. Man S, RI Lechler, JR Batchelor, and CE Sharrock. Individual variation in the frequency of HLA class II-specific cytotoxic T lymphocyte precursors. Eur J Immunol 1990;20:847-854.
26. Lukacher AE, LA Morrison, VL Braciale, et al. Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones. J Exp Med 1985;162:171-187.
27. McCarthy SA and A Singer. Recognition of MHC class I allodeterminants regulates the generation of MHC class II-specific CTL. J Immunol 1986;137:3087-3092.
28. Appay V, JJ Zaunders, L Papagno, et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002;168:5954-5958.
29. Yue FY, CM Kovacs, RC Dimayuga, et al. HIV-1-specific memory CD4+ T cells are phenotypically less mature than cytomegalovirus-specific memory CD4+ T cells. J Immunol 2004;172:2476-2486.
30. van de Berg PJ, EM van Leeuwen, IJ ten Berge, and R van Lier. Cytotoxic human CD4(+) T cells. Curr Opin Immunol 2008;20:339-343.
31. Appay V. The physiological role of cytotoxic CD4(+) T-cells: The holy grail? Clin Exp Immunol 2004;138:10-13.
32. van Leeuwen EM, EB Remmerswaal, MT Vossen, et al. Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004;173:1834-1841.
33. De Jong R, M Brouwer, B Hooibrink, et al. The CD27- subset of peripheral blood memory CD4 +lymphocytes contains functionally differentiated T lymphocytes that develop by persistent antigenic stimulation in vivo. Eur J Immunol 1992;22:993-999.
34. Snyder MR, M Lucas, E Vivier, et al. Selective activation of the c-Jun NH2- terminal protein kinase signaling pathway by stimulatory KIR in the absence of KARAP/DAP12 in CD4+ T cells. J Exp Med 2003;197:437-449.
35. Saez-Borderias A, M Guma, A Angulo, et al. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. Eur J Immunol 2006;36:3198-3206.
36. van Bergen J, A Thompson, A Van Der Slik, et al. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J Immunol 2004;173:6719-6726.
37. Wolthers KC, SA Otto, SM Lens, et al. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells. Eur J Immunol 1996;26:1700-1706.
38. Waldmann TA and Y Tagaya. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999;17:19-49.
39. Tortorella C, H Schulze-Koops, R Thomas, et al. Expression of CD45RB and CD27 identifies subsets of CD4+ memory T cells with different capacities to induce B cell differentiation. J Immunol 1995;155:149-162.
40. Shresta S, CT Pham, DA Thomas, et al. How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998;10:581-587.
41. Lowin B, F Beermann, A Schmidt, and J Tschopp. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity. Proc Natl Acad Sci U S A 1994;91:11571-11575.
42. Hahn S, R Gehri, and P Erb. Mechanism and biological significance of CD4- mediated cytotoxicity. Immunol Rev 1995;146:57-79.
43. Stalder T, S Hahn, and P Erb. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994;152:1127-1133.
44. Vergelli M, B Hemmer, PA Muraro, et al. Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol 1997;158:2756-2761.
45. Esser MT, RD Dinglasan, B Krishnamurthy, et al. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4 +T lymphocyte clones. J Immunol 1997;158:5612-5618.
46. Williams NS and VH Engelhard. Perforin-dependent cytotoxic activity and lym- phokine secretion by CD4+ T cells are regulated by CD8+ T cells. J Immunol 1997;159:2091-2099.
47. Kayagaki N, N Yamaguchi, M Nakayama, et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999;162:2639-2647.
48. [48 F Yanai, E Ishii, K Kojima, et al. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells. J Immunol 2003;170:2205-2213.
49. Brown DM, C Kamperschroer, AM Dilzer, et al. IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. Cell Immunol 2009;257:69-79.
50. Mauri D and WJ Pichler. Involvement of CD80 in the generation of CD4+ cytotoxic T cells. Immunol Res 1996;15:126-140.
51. Kebir H, K Kreymborg, I Ifergan, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13:1173-1175.
52. Janssens W, V Carlier, B Wu, et al. CD4+CD25+ T cells lyse antigen-presenting B cells by Fas-Fas ligand interaction in an epitope-specific manner. J Immunol 2003;171:4604-4612.
53. Suzuki M, A Sugimoto, A Harashima, et al. Novel mechanisms of suppressor activity exhibited by cytotoxic regulatory T cell lines, HOZOT. Exp Hematol 2009;37:92-100.
54. Kawamura K, N Kadowaki, T Kitawaki, and T Uchiyama. Virus-stimulated plasmacytoid dendritic cells induce CD4+ cytotoxic regulatory T cells. Blood 2006;107:1031-1038.
55. Restifo NP, FM Marincola, Y Kawakami, et al. Loss of functional beta 2- microglobulin in metastatic melanomas from five patients receiving immunother- apy. J Natl Cancer Inst 1996;88:100-108.
56. Khong HT and NP Restifo. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
57. Heller KN, C Gurer, and C Munz. Virus-specific CD4+ T cells: Ready for direct attack. J Exp Med 2006;203:805-808.
58. Mumberg D, PA Monach, S Wanderling, et al. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 1999;96:8633-8638.
59. Marsh SG, ED Albert, WF Bodmer, et al. Nomenclature for Factors of the HLA System, 2004. Hum Immunol 2005;66:571-636.
60. Foulds KE, LA Zenewicz, DJ Shedlock, et al. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol 2002;168:1528-1532.
61. Guidotti LG and FV Chisari. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
62. Seder RA and R Ahmed. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 2003;4:835-842.
63. Hamann D, PA Baars, MH Rep, et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 1997;186:1407-1418.
64. Laouar Y and IN Crispe. Functional flexibility in T cells: Independent regulation of CD4+ T cell proliferation and effector function in vivo. Immunity 2000;13: 291-301.
65. Aslan N, C Yurdaydin, J Wiegand, et al. Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat 2006;13:505-514.
66. Rizzetto M. Hepatitis D: Virology, clinical and epidemiological aspects. Acta Gas- troenterol Belg 2000;63:221-224.
67. Rothstein TL, JK Wang, DJ Panka, et al. Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 1995;374:163-165.
68. Cao T, P Meuleman, I Desombere, et al. In vivo inhibition of anti-hepatitis B virus core antigen (HBcAg) immunoglobulin G production by HBcAg-specific CD4(+) Th1-type T-cell clones in a hu-PBL-NOD/SCID mouse model. J Virol 2001;75:11449-11456.
69. Monie A, SW Tsen, CF Hung, and TC Wu. Therapeutic HPV DNA vaccines. Expert Rev Vaccines 2009;8:1221-1235.
70. Bosch FX, A Lorincz, N Munoz, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-265. (Pubitemid 34293391)
71. Facchinetti V, S Seresini, R Longhi, et al. CD4+ T cell immunity against the human papillomavirus-18 E6 transforming protein in healthy donors: Identification of promiscuous naturally processed epitopes. Eur J Immunol 2005;35:806-815.
72. Coleman N, HD Birley, AM Renton, et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994;102:768-774.
73. Bontkes HJ, TD de Gruijl, AJ Van Den Muysenberg, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000;88:92-98.
74. Luxton JC, R Nath, N Derias, et al. Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment. J Gen Virol 2003;84:1063-1070.
75. Gandhi MK and R Khanna. Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004;4:725-738.
76. Khan N, A Hislop, N Gudgeon, et al. Herpesvirus-specific CD8 T cell immunity in old age: Cytomegalovirus impairs the response to a coresident EBV infection. J Immunol 2004;173:7481-7489.
77. Gamadia LE, RJ Rentenaar, RA van Lier, and IJ ten Berge. Properties of CD4(+) T cells in human cytomegalovirus infection. Hum Immunol 2004;65:486-492.
78. Bitmansour AD, SL Waldrop, CJ Pitcher, et al. Clonotypic structure of the human CD4+ memory T cell response to cytomegalovirus. J Immunol 2001;167:1151-1163.
79. Crompton L, N Khan, R Khanna, et al. CD4+ T cells specific for glycoprotein B from cytomegalovirus exhibit extreme conservation of T-cell receptor usage between different individuals. Blood 2008;111:2053-2061.
80. Hegde NR, C Dunn, DM Lewinsohn, et al. Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL. J Exp Med 2005;202:1109-1119.
81. Elkington R, NH Shoukry, S Walker, et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol 2004;34:3216-3226.
82. Munz C. Epstein-Barr virus nuclear antigen 1: From immunologically invisible to a promising T cell target. J Exp Med 2004;199:1301-1304.
83. Paludan C, D Schmid, M Landthaler, et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 2005;307:593-596.
84. Gessain A, F Barin, JC Vernant, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985;2:407-410.
85. Osame M, K Usuku, S Izumo, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986;1:1031-1032. (Pubitemid 16102987)
86. Hanabuchi S, T Ohashi, Y Koya, et al. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: Peptide-induced T-cell immunity. J Natl Cancer Inst 2001;93:1775-1783.
87. Venturini S, DE Mosier, DR Burton, and P Poignard. Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization. J Virol 2002;76:6987-6999.
88. Zheng N, M Fujiwara, T Ueno, et al. Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages. J Virol 2009;83:7668-7677.
89. Jameson J, J Cruz, and FA Ennis. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 1998;72:8682-8689.
90. Hudrisier D, MB Oldstone, and JE Gairin. The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules. Virology 1997;234:62-73.
91. Vitiello A, L Yuan, RW Chesnut, et al. Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunol 1996;157:5555-5562.
92. Richards KA, FA Chaves, FR Krafcik, et al. Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin. J Virol 2007;81:7608-7619.
93. Gelder CM, JR Lamb, and BA Askonas. Human CD4+ T-cell recognition of influenza A virus hemagglutinin after subunit vaccination. J Virol 1996;70: 4787-4790.
94. Gelder C, M Davenport, M Barnardo, et al. Six unrelated HLA-DR-matched adults recognize identical CD4+ T cell epitopes from influenza A haemagglutinin that are not simply peptides with high HLA-DR binding affinities. Int Immunol 1998;10:211-222.
95. Hung K, R Hayashi, A Lafond-Walker, et al. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368.
96. Pardoll DM and SL Topalian. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-594.
97. Houghton AN, JS Gold, and NE Blachere. Immunity against cancer: Lessons learned from melanoma. Curr Opin Immunol 2001;13:134-140.
98. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22:269-276.
99. Ohminami H, M Yasukawa, S Kaneko, et al. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood 1999;93:925-935.
100. Schultz ES, B Schuler-Thurner, V Stroobant, et al. Functional analysis of tumor- specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy. J Immunol 2004;172:1304-1310.
101. Takahashi T, PB Chapman, SY Yang, et al. Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 1995;154:772-779.
102. Darrow TL, Z Abdel-Wahab, MA Quinn-Allen, and HF Seigler. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA- A2. Cell Immunol 1996;172:52-59.
103. Nishimura MI, D Avichezer, MC Custer, et al. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res 1999;59:6230-6238.
104. Zennadi R, Z Abdel-Wahab, HF Seigler, and TL Darrow. Generation of melanoma- specific, cytotoxic CD4(+) T helper 2 cells: Requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. Cell Immunol 2001;210:96-105.
105. Huarte E, J Karbach, S Gnjatic, et al. HLA-DP4 expression and immunity to NY- ESO-1: Correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. Cancer Immun 2004;4:15.
106. Toes RE, F Ossendorp, R Offringa, and CJ Melief. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189:753-756.
107. Zarour HM, WJ Storkus, V Brusic, et al. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res 2000;60:4946-4952.
108. Zeng G, CE Touloukian, X Wang, et al. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 2000;165:1153-1159.
109. Ostrand-Rosenberg S. CD4+ T lymphocytes: A critical component of antitumor immunity. Cancer Invest 2005;23:413-419.
110. Hunder NN, H Wallen, J Cao, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008;358:2698-2703
111. Muranski P and NP Restifo. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009;21:200-208.
112. Dudley ME, J Wunderlich, MI Nishimura, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001;24:363-373.
113. Porakishvili N, L Kardava, AP Jewell, et al. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway. Haematologica 2004;89:435-443.
114. Gladden AB, R Woolery, P Aggarwal, et al. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006;25:998-1007.
115. Gautschi O, D Ratschiller, M Gugger, et al. Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation. Lung Cancer 2007;55:1-14.
116. Gladden AB and JADiehl. Location, location, location: The role of cyclin D1 nuclear localization in cancer. J Cell Biochem 2005;96:906-913.
117. Dao T, T Korontsvit, V Zakhaleva, et al. Identification of a human cyclin D1- derived peptide that induces human cytotoxic CD4 T cells. PLoS One 2009;4:e6730.
118. Haque T, GM Wilkie, MM Jones, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007;110:1123-1131.
119. Javier RT and JS Butel. The history of tumor virology. Cancer Res 2008;68: 7693-7706.
120. Young LS and AB Rickinson. Epstein-Barr virus: 40 years on. Nat Rev Cance 2004;4:757-768.
121. Merlo A, R Turrini, R Dolcetti, et al. Adoptive cell therapy against EBV-related ma lignancies: A survey of clinical results. Expert Opin Biol Ther 2008;8:1265-1294
122. Hislop AD, GS Taylor, D Sauce, and AB Rickinson. Cellular responses to vi ral infection in humans: Lessons from Epstein-Barr virus. Annu Rev Immuno 2007;25:587-617.
123. Haigh TA, X Lin, H Jia, et al. EBV latent membrane proteins (LMPs) 1 and as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition o EBV-transformed B cell lines. J Immunol 2008;180:1643-1654.
124. Rooney CM, CA Smith, CY Ng, et al. Use of gene-modified virus-specific r lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lance 1995;345:9-13.
125. Heslop HE, KS Slobod, MA Pule, et al. Long term outcome of EBV specific T-cell in fusions to prevent or treat EBV-related lymphoproliferative disease in transplan recipients. Blood 2010;115:925-935.
126. Sun Q, RL Burton, and KG Lucas. Cytokine production and cytolytic mechanisn of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Bar virus-specific T-cell cultures. Blood 2002;99:3302-3309.
127. Khanolkar A, H Yagita, and MJ Cannon. Preferential utilization of the per forin/granzyme pathway for lysis of Epstein-Barr virus-transformed lymphoblas toid cells by virus-specific CD4+ T cells. Virology 2001;287:79-88.
128. Wilson AD, I Redchenko, NA Williams, and AJ Morgan. CD4+ T cells inhibi growth of Epstein-Barr virus-transformed B cells through CD95-CD95 ligand mediated apoptosis. Int Immunol 1998;10:1149-1157.
129. MacArthur GJ, AD Wilson, MA Birchall, and AJ Morgan. Primary CD4+ T-cel responses provide both helper and cytotoxic functions during Epstein-Barr viru infection and transformation of fetal cord blood B cells. J Virol 2007;81:4766-4775
130. Adhikary D, U Behrends, A Moosmann, et al. Control of Epstein-Barr virus in fection in vitro by T helper cells specific for virion glycoproteins. J Exp Me 2006;203:995-1006.
131. Adhikary D, U Behrends, H Boerschmann, et al. Immunodominance of lytic cycli antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLof ONE 2007;2:e583.
132. Taylor GS, HM Long, TA Haigh, et al. A role for intercellular antigen transfer i] the recognition of EBV-transformed B cell lines by EBV nuclear antigen-specifi CD4+ T cells. J Immunol 2006;177:3746-3756.
133. Perrine SP, O Hermine, T Small, et al. A phase 1/2 trial of arginine butyrate an( ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies Blood 2007;109:2571-2578.
134. Feng WH, B Israel, N Raab-Traub, et al. Chemotherapy induces lytic EBV replica tion and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors Cancer Res 2002;62:1920-1926.
135. Israel BF and SC Kenney. Virally targeted therapies for EBV-associated malig nancies. Oncogene 2003;22:5122-5130.
136. Long HM, J Zuo, AM Leese, et al. CD4+ T-cell clones recognizing humai lymphoma-associated antigens: Generation by in vitro stimulation with autolo gous Epstein-Barr virus-transformed B cells. Blood 2009;114:807-815.
137. Rooney CM, CA Smith, CY Ng, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplan recipients. Blood 1998;92:1549-1555.
138. Su Z, MV Peluso, SH Raffegerst, et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol 2001;31:947-958.
139. Omiya R, C Buteau, H Kobayashi, et al. Inhibition of EBV-induced lymphopro- liferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol 2002;169:2172-2179.
140. Landais E, X Saulquin, E Scotet, et al. Direct killing of Epstein-Barr virus (EBV)- infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood 2004;103:1408-1416.
141. Voo KS, T Fu, HY Wang, et al. Evidence for the presentation of major histocom- patibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med 2004;199:459-470.
142. Lee SP, JM Brooks, H Al-Jarrah, et al. CD8 T cell recognition of endoge- nously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med 2004;199: 1409-1420.
143. Tellam J, G Connolly, KJ Green, et al. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med 2004;199:1421-1431.
144. Bickham K, C Munz, ML Tsang, et al. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest 2001;107:121-130.
145. Paludan C, K Bickham, S Nikiforow, et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol 2002;169:1593-1603.
146. Fu T, KS Voo, and RF Wang. Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo. J Clin Invest 2004;114:542-550.
147. Mautner J, D Pich, F Nimmerjahn, et al. Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells. Eur J Immunol 2004;34:2500-2509.
148. Khanna R, SR Burrows, PM Steigerwald-Mullen, et al. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: Implications for viral persistence and tumor surveillance. Virology 1995;214:633-637.
149. Khanna R, SR Burrows, PM Steigerwald-Mullen, et al. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: Evidence for HLA-DM- independent processing. Int Immunol 1997;9:1537-1543.
150. Long HM, TA Haigh, NH Gudgeon, et al. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lym- phoblastoid cell lines. J Virol 2005;79:4896-4907.
151. Leung CS, TA Haigh, LK Mackay, et al. Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display. Proc Natl Acad Sci U S A 2010;107:2165-2170.
152. Heller KN, F Arrey, P Steinherz, et al. Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer 2008;123:2824-2831.
153. Moormann AM, KN Heller, K Chelimo, et al. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer 2009;124:1721-1726.
154. Lunemann JD, I Jelcic, S Roberts, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 2008;205:1763-1773.
155. Salvetti M, G Giovannoni, and F Aloisi. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 2009;22:201-206.
156. Toussirot E and J Roudier. Pathophysiological links between rheumatoid arthritis and the Epstein-Barr virus: An update. Joint Bone Spine 2007;74:418-426.
157. James JA, JB Harley, and RH Scofield. Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol 2006;18:462-467.
158. Demachi-Okamura A, Y Ito, Y Akatsuka, et al. Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci 2008;99:1633-1642.
159. Kobayashi H, T Nagato, M Takahara, et al. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res 2008;68:901-908.
160. Gudgeon NH, GS Taylor, HMLong, et al. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. J Virol 2005;79:5477-5488.
161. Voo KS, G Peng, Z Guo, et al. Functional characterization of EBV-encoded nuclear antigen 1-specific CD4+ helper and regulatory T cells elicited by in vitro peptide stimulation. Cancer Res 2005;65:1577-1586.
162. FuZ andMJ Cannon. Functional analysis of the CD4(+) T-cell responseto Epstein- Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. J Virol 2000;74:6675-6679.
163. Veronese ML, A Veronesi, E D'Andrea, et al. Lymphoproliferative disease inhuman peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumor generation. J Exp Med 1992;176:1763-1767.
164. Johannessen I, M Asghar, and DH Crawford. Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodefi- cient mice. Br J Haematol 2000;109:600-610.
165. Wagar EJ, MA Cromwell, LD Shultz, et al. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice. J Immunol 2000;165:518-527.
166. Nikiforow S, K Bottomly, G Miller, and C Munz. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 2003;77:12088-12104.
167. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007;117: 1466-1476.
168. Quezada SA, TR Simpson, KS Peggs, et al. Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-650.
169. Xie Y, A Akpinarli, C Maris, et al. Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010;207:651-667.